Phase 2 Alzheimer's Disease Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who completed the full treatment period in the related parent study (NCT06079190)
• People who may have missed some doses or had a temporary pause in treatment during the parent study, as long as they were not permanently removed from the study intervention or fully withdrawn from the parent study
• People who are willing and able to give informed consent, including agreeing to follow all study requirements and restrictions
• People who have a trusted adult in their life — such as a family member or close friend — who has regular, meaningful contact with them, can accurately describe their thinking and daily functioning abilities, is willing to attend clinic visits to provide information, and agrees to sign a study partner consent form
• Women who are not pregnant or breastfeeding, and who agree to follow the contraception requirements set out in the study protocol if there is any possibility of becoming pregnant
• Men who agree to follow the contraception requirements set out in the study protocol

Who may not be able to join:

• People whose heart rhythm measurement (a specific electrical interval in the heart) at the first study day meets certain stopping thresholds defined in the protocol
• People who are currently taking, or plan to start taking, any medication that is listed as prohibited in the study protocol
• People whose brain scans show certain types of imaging abnormalities related to amyloid (a protein linked to Alzheimer's disease) or large areas of bleeding in the brain that meet the criteria for permanent removal from the study
• People whose brain scans show other newly found concerns, such as bleeding, abnormal blood vessels, infection, growths, tumours, or other findings that would make MRI-based participation unsafe
• People with a newly identified infection that may affect the brain or nervous system
• People with a new diagnosis of moderate to severe alcohol or substance use disorder
• People who have developed a new difficulty tolerating MRI scans, or who have a new medical reason that makes MRI unsafe or unsuitable
• People with a newly diagnosed cancer
• People with a newly identified severe allergic or hypersensitivity reaction to certain types of laboratory-made antibody-based treatments (confirm with trial site if unsure whether this applies)
• People with a newly identified inherited tendency toward blood clotting problems or bleeding disorders
• People with any other significant change in health that the trial doctor considers would make participation in this extension study inappropriate

Important: Always verify eligibility with the trial site directly before applying.